NCT03356678View on ClinicalTrials.gov

Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma

CompletedOBSERVATIONAL
Enrollment

33

Participants

Timeline

Start Date

September 23, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Relapsed or Refractory Peripheral T-cell Lymphoma
Interventions
DRUG

Pralatrexate

"* Patients treated with pralatrexate due to relapse or refractory disease after primary and/or salvage treatment. Relapse following an autologous stem cell transplant allowed.~* Patients treated with pralatrexate 30mg/m2 once a week for 6 weeks as part of a 7-week cycle. However, modified dose and/or schedule allowed."

Trial Locations (2)

135-710

Samsung Medical Center, Seoul

06351

81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT03356678 - Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma | Biotech Hunter | Biotech Hunter